Lebanon, New Hampshire – July 27, 2016 – Avitide, Inc., a biotech company dedicated to the discovery, manufacture, and supply of on-demand affinity purification solutions for the biopharmaceutical industry, announced that it has secured a long-term lease agreement for the former Merck & Co., Inc. – GlycoFi facility at the Dartmouth Regional Technology Center. The facility will serve as Avitide’s new headquarters for discovery and manufacturing operations.
“This new facility will quadruple Avitide’s R&D and manufacturing operations. The new space will support affinity resin discovery and development through manufacturing and supply for the life of each novel affinity separation product. Securing this long-term facility agreement reinforces Avitide’s commitment to become the world-leader in exclusive affinity separation technologies for preclinical, clinical and commercial biologics, vaccines, and gene therapies,” said Kevin Isett, Avitide’s CEO and co-founder.
The Avitide technology enables its partners to discover and develop exclusive, high-performance affinity purification technologies. Avitide’s 3-month service improves partner timelines, economics, and manufacturing control of biologics, vaccines, and gene therapies. Avitide’s management team brings substantial expertise and a track record of success in commercializing innovative biopharmaceutical discovery and manufacturing platform technologies. Avitide is financed by premier venture capital firms such as Polaris Venture Partners, OrbiMed Advisors, SV Life Sciences, NeoMed Management, and Borealis Ventures.
The Dartmouth Regional Technology Center, Inc. (DRTC) is a private, non-profit organization formed in 2004 to assist start-up and high-growth businesses with a 60,500 square foot mixed use technology incubator to foster the development of technology and biotechnology companies in New Hampshire. For more information, contact email@example.com.
Avitide delivers on-demand, molecule-specific biopharmaceutical affinity purification solutions with an industry-leading 3-month service. Avitide’s proprietary affinity separation technology enables our partners to achieve faster bioprocess development timelines, reduced program risk, predictable commercial scalability, and lower cost of manufacturing. Avitide’s high-resolution affinity resins also select and enrich for drug safety, potency, and quality attributes critical to controlling target product profiles and establishing biosimilarity. For more information, contact firstname.lastname@example.org.